Aperçu des produits pour anti-MORC Family CW-Type Zinc Finger 3 (MORC3) Anticorps

Mouse (Murine) MORC Family CW-Type Zinc Finger 3 (MORC3) interaction partners

1. Data show that the MORC3 N-terminal ATPase (Montrer DNAH8 Anticorps) domain forms a dimer when bound to AMPPNP.

2. Data indicate that Morc3 mutation leads to altered nuclear localization of the protein, and upregulation of the IFN-beta (Montrer IFNB1 Anticorps) /STAT1 (Montrer STAT1 Anticorps) pathway, which plays a critical role in the maintenance of bone homeostasis. These findings establish Morc3 as a previously unreported regulator of cortical bone homeostasis and haematopoietic stem cells niche, accompanied by altered bone cell differentiation.

3. MORC3 colocalizes with PML (Montrer PML Anticorps) by a two-step molecular mechanism.

4. MORC3 (microrchidia3)-ATPase (Montrer DNAH8 Anticorps) activated p53 (Montrer TP53 Anticorps) and induced cellular senescence in normal fibroblasts but not p53 (Montrer TP53 Anticorps)-/- fibroblasts

Human MORC Family CW-Type Zinc Finger 3 (MORC3) interaction partners

1. our studies provide a molecular framework detailing MORC3 functions and suggest that its modulation may contribute to human disease.

2. Dermatomyositis patients with anti-NXP-2 antibodies have a distinct and often severe systemic phenotype that includes myalgia, peripheral edema, and significant dysphagia, despite having milder inflammatory skin disease.

3. MORC3 has antiviral activity during herpes simplex virus 1 and human cytomegalovirus infections.

4. Downregulation of NXP2/MORC3 by use of two independent short hairpin RNAs reduced virus titers in low-multiplicity infections. Analysis of viral RNA in high-multiplicity infections showed a reduction of viral RNA and mRNA after NXP2/MORC3 downregulation.

5. Case Report: Pemphigus foliaceus (Montrer DSG1 Anticorps) associated with anti-NXP2 autoantibody-positive amyopathic dermatomyositis.

6. These studies demonstrate that anti-NXP-2 and anti-TIF (Montrer TYRO3 Anticorps)-1gamma antibodies are frequent DM specificities (found in 55% of patients) and are present in most patients with cancer-associated dermatomhyositis.

7. An anti-MJ antibody that recognizes NXP-2 was found to be a useful biomarker in dermatomyositis-polymyositis patients.

8. Anti-NXP2 Ab may be associated with adult idiopathic inflammatory myopathies with malignancy.

9. MORC3 colocalizes with PML (Montrer PML Anticorps) by a two-step molecular mechanism.

10. When tethered to a promoter by fusion to Gal4, NXP-2 repressed transcription, consistent with a role for NXP-2 in SUMO-mediated repression